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Edited by Jesus AvilaAbstract Many disorders, including Alzheimers, the prion
encephalopathies and other neurodegenerative diseases, result
from aberrant protein aggregation. Surprisingly, cellular toxicity
is often due not to the highly-ordered aggregates but to the olig-
omers that precede their formation. Using serpins as a paradigm,
we show how the active and infective interface of oligomers is
inherently toxic and can promiscuously bind to unrelated pep-
tides, including neurotransmitters. Extension of the oligomer
and its eventual sequestration as amyloid can thus be seen as a
protective response to block the toxic interface. We illustrate
how the preferential self-association that gives this protection
has been selectively favoured.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V.
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The protein aggregation that underlies conformational dis-
eases such as the prevalent Alzheimers, Parkinsons and prion
encephalopathies [1–4], is due not to random addition but to
sequential b-interlinkages resulting in progressive ﬁbral elon-
gation [5,6]. The end-point of these progressive b-linkages is
the formation of highly-ordered ﬁbrillar and amyloid deposits.
The presence in many of the conformational diseases of readily
recognisable amyloid deposits led to the presumption that the
diseases themselves were due to the formation of amyloid. The
massive deposition of amyloid can indeed result in organ fail-
ure but for the most part and particularly with the neurodegen-
erative diseases, the appearance of amyloid deposits is a late
and inconsistent feature. Similarly the accumulation of long-
chain protein polymers can directly aﬀect cellular viability [7]
but there is now increasing evidence that cellular damage
and speciﬁcally neurotoxicity often arises much earlier in
the disease process, at the stage of initial oligomer formation
[8–12]. The generality of this unexpected ﬁnding [13]. indicates
a shared mechanism. This has focused our attention on the one
mechanistic feature common to all the conformational dis-
eases, the formation of the intermolecular b-bonding responsi-
ble for the protein aggregation.
To determine why early oligomers formed by such linkages
are consistently toxic we have examined the b-interlinkages*Corresponding author. Address: Trinity College, Cambridge CB2
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protease inhibitors, the serpins [6,14]. The advantage of using
the serpins as a model is that the mechanism of their ﬁbrillar
aggregation is known in crystallographic detail [15,16]. The
inhibitory eﬃciency of the serpins is dependent on the ability
of their cleaved reactive–centre peptide loop to insert into
the middle-strand position of the 5-stranded b-sheet A of the
molecule. This ability of the A b-sheet to undergo a transition
from a 5- to a 6-stranded form makes the serpins susceptible to
intermolecular linkages, as an aberrant opening of the A-sheet
allows the insertion into it of the reactive loop of another mol-
ecule (Fig. 1). The sequential formation of similar domain ex-
changes in a number of other proteins likewise results in
oligomer and polymer formation in a process descriptively
summarised as runaway domain swapping [17]. This notably
occurs with the plasma serpin a1-antitrypsin that protects the
lungs against the proteases released by inﬂammatory cells.
People of European descent commonly carry the unstable Z-
variant of a1-antitrypsin that readily forms loop-sheet poly-
mers. The polymerisation of Z-antitrypsin [18] principally
takes place at its site of synthesis in the hepatocyte and its
accumulation there, as intracellular inclusions, is in itself dam-
aging and leads to the eventual development of liver cirrhosis.
By a precisely similar process, mutations in a neurone-speciﬁc
serpin can result in its intracellular polymerisation in neurones
leading to an Alzheimer-like late-onset encephalopathy and
dementia [7,19].
We have recently shown [20] that the initiating step in serpin
polymerisation occurs when two molecules with coincidentally
perturbed conformations link to form an initial dimer with two
active interfaces (Figs. 1 and 2a). In one unit of the dimer the
A-sheet is stabilised in a partially opened form, making it an
activated acceptor for b-strand linkages, whereas the other
unit has an exposed reactive centre peptide loop held in a
constrained conformation optimal for b-strand donation.
Once it is formed this nucleating and infective oligomer
can then recruit further molecules resulting in a sequential
re-formation, molecule by molecule, of each of the active inter-
faces [20]. We show here, with the serpins a1-antitrypsin and
antithrombin, how the exposed b-acceptor interface of such
oligomers is potentially toxic in that it can promiscuously link
to neurotransmitter and other vital peptides. This toxicity will
be limited however by the competitive blocking of the site by
auto-linkages resulting in the progressive extension of the oli-
gomer and its eventual sequestration. An indication as to why
self-association is so competitively successful comes from the
demonstration here of a b-bonding interface in antithrombin
that is constantly being exposed in blood but is immediately
and preferentially blocked by a speciﬁc auto-linkage.by Elsevier B.V. Open access under CC BY license.
Fig. 1. Serpin b-interfaces and linkages. Crystallographic depictions: (a) Cleavage of the reactive centre loop (red) of a1-antitrypsin creates a b-donor
strand I, and an accompanying opening of the A-sheet (blue) creates a b-acceptor site II. Subsequent interlinkage, as shown with the dimer, re-forms
each of these sites as the oligomer extends (PDB 1QMB) [15]. (b) The hexapeptide acceptor site II seen here in a polymerogenic form of antithrombin
[25], can promiscuously bind other peptides including as shown the neurotransmitter peptide CCK4 (PDB 1JVQ). But even the peptide that naturally
occupies this site, TAVVIA, has to be in a 100-fold excess to compete with the preferential linkage to the site of another molecule of antithrombin. (c)
The potential promiscuity and hence toxicity of a vacated b-acceptor site is seen here with exposure of the s1C strand position in a1-antitrypsin (see
also Fig. 3a) and the binding to it of a liposaccharide from Im et al (PDB 1IZ2) [30].
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2.1. Materials
Human a-antithrombin (ATIII) and a1-antitrypsin (a1AT) were
puriﬁed from frozen plasma as previously described [18,21]. Polymers
of ATIII or a1AT were prepared by heating the protein at 60 C for
15 min at 1 mg/ml at pH7.4 or by PP4 protease cleavage [22]. Human
a1AT mutants with P7-P3 of the reactive loop substituted to AVVIA
(P7-P3 of the reactive loop of ATIII) or VTFKA (strand 1 of C-sheet
of ATIII) were prepared from E. coli and puriﬁed using nickel-chelat-
ing and ionic exchange HiTrap Q columns (GE Healthcare) as previ-
ously described [23]. Peptides CCK4 (WMDF), CCK6 (DYMGWM)
and C.NP, the cardioexcitatory neuropeptide (FLRF),were from Sig-
ma–Aldrich Ltd., Dorset, England. Latent antithrombin and its di-
meric derivatives were prepared and characterised as previously
described [21,24].
2.2. Biotin labelling
To label the only cysteine residue of a1AT with biotin, plasma
a1AT was ﬁrst treated with 10 mM DTT, pH 7.4, at room temperature
for 15 min and puriﬁed from free DTT by a NAP10 desalting column.
A freshly-made solution of N-(3-maleimidylpropiony)biocytin (Molec-
ular Probes) was added to the protein solution (1 mg/ml) at 10 molar
excess and the mixture was kept at room temperature for 2 h. The reac-
tion was stopped by adding 10 mM DTT and the labelled a1AT was
puriﬁed by a Hitrap Q column. To detect the biotin labelled protein,
samples were analysed by native gel electrophoresis, and then trans-
ferred to a nitrocellulose membrane, blotted with streptavidin-peroxi-
dase polymer (Sigma) and visualised using the ECL Western Blotting
Detection Regents (GE healthcare). Native gel electrophoresis was per-
formed as previously described using an 8% polyacrylamide gel [24].3. Results and discussion
3.1. Toxic interface
The potential toxicity of the activated b-interface of early
oligomers, is demonstrated in Fig. 2b with the polymerisation
of a1-antitrypsin induced by cleavage of its reactive loop by
the protease PP4 [15,16,22]. This shows the relatively non-spe-
ciﬁc amino acid sequence requirement for b-strand linkage to
the acceptor interface, with polymerisation being blocked not
only by the annealing of the b-strand peptide that normally
occupies the acceptor interface in a1-antitrypsin (FLEAI)but also, with even greater eﬃciency, by the equivalent but
quite diﬀerent peptide from antithrombin (TAVVIA) [25]. As
shown the interface can also bind with equal eﬃciency to a
range of other small peptides, including the cholecystokinin
neuropeptides CCK6 (DYMGWM) and CCK4 (WMDF)
and the cardioexcitatory neuropeptide C.NP (FLRF). The
ability to bind to heterogeneous peptide sequences in this
way is not conﬁned to the polymers of a1-antitrypsin induced
by loop cleavage but also occurs with the heat-induced oligo-
mers of polymerogenic forms of antithrombin and with mutant
Z a1-antitrypsin [25]. This inherent ability of oligomers to pro-
miscuously form b-linkages with a range of peptides, explains
their potential toxicity. Although this potential toxicity is dem-
onstrated here with the ready ability to bind neurotransmitter
and other peptide messengers, lethal damage is more likely to
occur within the milieu of the cell due to a similar binding to
the peptide loops of receptors [26] or of other key cellular
and membrane components [27]. But protection against such
promiscuous and potentially lethal linkages will be provided
by the much more competitively avid formation of auto-link-
ages.
3.2. Speciﬁcity of auto-linkages
Although we show in Fig. 2b the blockage of polymer exten-
sion by various peptides, unless the competing peptide is pres-
ent in greater than 50:1 molar ratio with respect to the
monomer[25,28] serpin oligomers will preferentially link with
further serpin monomers to give oligomeric extension and
polymerisation. Moreover the auto-linkage is relatively speciﬁc
for each serpin. As shown in Fig. 2c, monomers of a1-antitryp-
sin readily link to pre-formed polymers of a1-antitrypsin but
only detectably so to polymers of the closely related serpin,
antithrombin. Such preferential auto-linkages are readily
explicable if they involve major domain exchanges but the sur-
prising ﬁnding is that preferential auto-linkage also takes place
even when the linkage involves only a small 6-residue peptide
sequence, as with the polymerogenic serpins depicted in Fig. 1a
and b. We conclude that the interlinkage of serpins is depen-
dent not only on strand sequences but also requires a confor-
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occurs spontaneously, at 37 C, with the unstable variants
associated with disease. Hence the aggregates of a1-antitrypsin
in the hepatocytes that cause the associated cirrhosis are
homogeneous and contain only the abnormal Z-variant and
similarly the neuronal aggregates in the neuroserpin encepha-
lopathies contain only the variant neuroserpin despite the pres-
ence of the normal allelic protein.
A clear example of how the speciﬁcity of this self-association
has been inﬂuenced by selective design comes from observa-
tions of another conformational change in a plasma serpin
(Fig. 3). Each day, in everyone, some 4% of the total circulat-
ing antithrombin undergoes a senescent conformational transi-
tion to an inactive latent form with a 6-stranded A-sheet
[21,24,29]. This addition of an extra strand to the A-sheet is
accompanied by the removal of the outer strand from another
b-sheet of the molecule, the C-sheet. The potential for this va-
cant and exposed b-strand position in the C-sheet to form
potentially toxic linkages is seen with a1-antitrypsin in Fig.Fig. 2. Oligomer extension and toxicity. (a) Oligomer formation in the
intact serpins results from the formation of an initiating dimer [20]
shown diagrammatically here, labelled as in the cleaved dimer in Fig.
1a. (b) Native PAGE (and table of reactive centre loop sequences).
Polymerisation of plasma a1-antitrypsin (a1AT) is readily induced
[15,22] by loop-cleavage with the protease PP4 but is blocked by
incubation [25] at 37 C of a 100-fold molar excess of the peptide
FLEIAG that normally occupies this strand vacancy in a1-antitrypsin,
but also equally eﬀectively not only by the homologous peptide
TAVVIA from antithrombin (ATIII) but also by the cholecystokinin
peptides CCK4 and CCK6 and the cardioexcitatory neuropeptide
C.NP. (c) Native PAGE of biotin-labelled a1-antitrypsin (a1ATb) at
0.1 mg/ml incubated at 50 C for 0–24 h and visualised with a
chemiluminescent substrate [20]. P, polymer marker and left three
lanes with control unlabelled a1-antitrypsin (0.5 mg/ml). Middle three
lanes show that addition of 0.5 mg/ml of pre-formed a1-antitrypsin
polymers (a1ATp) results in the polymerisation and consumption of
the labelled monomer. A similar addition of 0.5 mg/ml polymers
(ATIIIp) of antithrombin in the three lanes on right shows that
heterogeneous interlinkage does occur but not to an extent that
discernibly consumes the monomeric a1-antitrypsin (Mo).1c [30]. In antithrombin however, the vacant b-strand position
is immediately ﬁlled and blocked by linkage to it of the reactive
centre loop of an active molecule of antithrombin to give an
active-latent heterodimer (Fig. 3a, iii). The sequence of the
peptide section (AVVIA) of the reactive loop of active anti-
thrombin that occupies the vacated site in the C-sheet in the
latent molecule bears no apparent relationship to that of the
displaced strand (VTFKA). This then seems a relatively non-
speciﬁc linkage and we fully expected that the addition of puri-
ﬁed latent antithrombin to plasma would result in a number of
similarly non-speciﬁc linkages to other plasma proteins. But to
our surprise the only detectable linkage, which accounted for
all the added latent antithrombin, was to active plasma anti-
thrombin. To further examine the speciﬁcity of this linkage
we incubated latent antithrombin with a series of other plasma
serpins all of which have exposed peptide loops. A weakly
linked dimer was formed with antichymotrypsin that was read-
ily displaced by antithrombin (not shown) but there was no
linkage with other serpins including a1-antitrypsin. The speci-
ﬁcity of linkage was also tested using the Pittsburgh variant of
a1-antitrypsin in which the reactive centre methionine of a1-
antitrypsin is replaced by an arginine as is present in anti-
thrombin (Fig. 3b). The wild-type antitrypsin-Pittsburgh did
not form a dimer with latent antithrombin but dimers were
formed when the reactive centre loop of the Pittsburgh anti-
trypsin was homologously modiﬁed to the AVVIA sequence
present in the reactive loop of antithrombin but not when
the sequence was modiﬁed to the VTFKA of the displaced
C-sheet strand. The explanation for these ﬁndings is clear on
examination of the crystal structure of the heterodimer [31].
The intermolecular linkage between the latent and active mol-
ecules involves a number of contacts outside and beyond those
formed by the replacement strand. In particular the reactive
centre arginine present in antithrombin, and also in antitryp-
sin-Pittsburgh, forms a pair of hydrogen bonds that link the
two molecules with a structural speciﬁcity that is persuasively
purposeful (Fig. 3a, v). Thus as soon as the latent molecule is
formed a speciﬁc interaction with an active molecule of anti-
thrombin eﬀectively blocks the exposed b-interface, pending
the catabolic removal of the senescent molecule. Although this
may be an extreme example, the homogeneity of the oligomers
formed by other serpins (Fig. 2c) similarly indicates a preferen-
tial and inherent conformational complementarity.3.3. Why is amyloid so ubiquitous?
The presence of amyloid deposits is such a frequent and evi-
dent ﬁnding in the conformational diseases that they have of-
ten been referred to collectively as the amyloidoses. But if
amyloid is not the toxic species, why then is its presence so
ubiquitous? An accompanying puzzle for protein chemists is
why, if b-linkages are non-demanding, is amyloid so homoge-
neous? It is no surprise that puriﬁed proteins, if unfolded in vi-
tro, form ordered and sequential intermolecular b-linkages.
The puzzle comes from the almost universal ﬁnding that even
in the complex mixtures that exist in vivo there is still a speciﬁc
and homogeneous self-association. This will in part reﬂect the
requirement for domain complementarity but as we illustrate
here, there has also been a selective adaptation of the struc-
tures of conformationally vulnerable molecules to favour inter-
molecular linkage, as a defensive response to the exposure of
active and potentially toxic b-interfaces. Not only does anti-
Fig. 3. Speciﬁcity of autolinkage and blockage of a b-interface. (a) The senescent transition of active antithrombin (i) to its latent form (ii) exposes a
vacated strand position (green, arrowed), see also Fig. 1c. This is immediately ﬁlled (iii) by the reactive loop, in red, of an active antithrombin
molecule to give formation of a heterodimer as seen (iv) on native-PAGE showing the addition of active antithrombin (N) to equimolar latent
antithrombin (L) [21,24]. (b) Native-PAGE showing dimer formation with latent antithrombin and recombinant variants of a1-antitrypsin (Table).
The Pittsburgh variant of a1-antitrypsin with a reactive centre arginine (Pitts) does not form a dimer if added to equimolar latent antithrombin, nor
does it if the sequence VTFKA of the displaced strand is inserted in the reactive centre loop (C2). But dimer formation does occur (C1) when this
sequence is replaced by that present in antithrombin AVVIA. The structural basis for this speciﬁcity of interlinkage and hence of the blocking of the
exposed b-acceptor site in latent antithrombin is indicated in the inset (v) expanded from (iii). This shows [31] the bridging of the two molecules by
the reactive centre arginine 393 as well as by the AVVIA strand (red) of the reactive centre loop of the active molecule.
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cated interface (Figs. 1c and 3a) but in the serpins in general,
exposure of a hexapeptide b-acceptor site (Fig. 1b) is compet-
itively ﬁlled by auto-linkages in a 50:1 preference to the natural
hexapeptide (Fig. 2b). This ability to preferentially form auto-
linkages enables the early oligomer to scavenge and selectively
remove molecules that may, even transitorily, change their
fold. The Conformational Diseases result from a great diver-
sity of oligomeric linkages - a diversity seen even within the
serpins which have at least ﬁve diﬀerent identiﬁed inter-strand
linkages [14] only two of which, to strands 1C and 4A, have
been illustrated here. The wider relevance of the ﬁndings from
the serpins is the demonstration, in structural detail, of the
consequences of the formation of active b-acceptor and donor
interfaces. Although we demonstrate this with the domain ex-
change and small-peptide interlinkage of ordered proteins thesame will apply with the oligomers formed by individual free
peptides, where recruitment similarly occurs, molecule by mol-
ecule, to an extendable terminal b-interface [32].
These simple concepts explain why ﬁbrillar deposits and
amyloid are such a ubiquitous feature of the conformational
diseases. The deposits can now be seen as the end-point of a
protective response [13,33] that sequestrates active and poten-
tially toxic interfaces. The ability of the oligomers to recruit
and extend also explains their inherent infectivity, with the
fragmentation of polymers initiating further rapid polymerisa-
tion [34]. The conformational changes that are induced in the
serpins on oligomer formation are reversible so the infectivity
is self-limiting. But a special danger will arise if the induced
conformational changes are irreversible, as with prions, to give
a progressive and cumulative infectivity. The overall conclu-
sions also have implications for approaches to treatment. A
R.W. Carrell et al. / FEBS Letters 582 (2008) 2537–2541 2541priority target for therapy is the blockage of the activated and
hence potentially toxic interface of the early oligomer. Para-
doxically, there may be circumstances where it is instead
advantageous to encourage oligomer extension in order to
sequestrate the b-interface.
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